SVB Leerink Initiates Coverage On Cytokinetics with Outperform Rating, Announces Price Target of $58
Portfolio Pulse from richadhand@benzinga.com
SVB Leerink analyst Roanna Ruiz has initiated coverage on Cytokinetics (NASDAQ:CYTK) with an Outperform rating and a price target of $58.
August 15, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cytokinetics has been given an Outperform rating by SVB Leerink with a price target of $58.
The Outperform rating from SVB Leerink indicates a positive outlook for Cytokinetics. The price target of $58 suggests a significant upside potential from the current price. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100